Medicaid “Best Price” Should Guide Medicare ASP Calculations, CMS Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Manufacturers may make “reasonable assumptions” based upon their business practices in the Medicaid program when calculating average sales price for Part B drugs. Companies should include such assumptions with their ASP data submissions, due April 30.